---
title: "醫療保健行業因資金輪動進入滯後板塊而上漲——醫療保健行業綜述"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/286822335.md"
description: "醫療公司獲得了收益，因為交易者將注意力轉向表現不佳的行業。然而，再生元製藥在其用於黑色素瘤的 fianlimab 藥物的晚期研究失敗後，股價大幅下跌。此外，一名美國人在剛果民主共和國感染了埃博拉病毒，正值疫情持續爆發之際"
datetime: "2026-05-18T21:34:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286822335.md)
  - [en](https://longbridge.com/en/news/286822335.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286822335.md)
---

# 醫療保健行業因資金輪動進入滯後板塊而上漲——醫療保健行業綜述

Health-care companies rose as traders rotated into some lagging sectors.

Regeneron Pharmaceuticals shares fell sharply in premarket trading Monday after the biotechnology company reported a late-stage study failure of its fianlimab drug candidate in the skin cancer melanoma.

An American contracted Ebola while working in the Democratic Republic of Congo, where the outbreak of the fatal virus is spreading.

Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

May 18, 2026 17:26 ET (21:26 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

### 相關股票

- [REGN.US](https://longbridge.com/zh-HK/quote/REGN.US.md)
- [PBE.US](https://longbridge.com/zh-HK/quote/PBE.US.md)
- [XLV.US](https://longbridge.com/zh-HK/quote/XLV.US.md)
- [IHE.US](https://longbridge.com/zh-HK/quote/IHE.US.md)
- [BIB.US](https://longbridge.com/zh-HK/quote/BIB.US.md)
- [SBIO.US](https://longbridge.com/zh-HK/quote/SBIO.US.md)
- [ARKG.US](https://longbridge.com/zh-HK/quote/ARKG.US.md)
- [XBI.US](https://longbridge.com/zh-HK/quote/XBI.US.md)
- [BBH.US](https://longbridge.com/zh-HK/quote/BBH.US.md)
- [VHT.US](https://longbridge.com/zh-HK/quote/VHT.US.md)
- [FBT.US](https://longbridge.com/zh-HK/quote/FBT.US.md)
- [IBB.US](https://longbridge.com/zh-HK/quote/IBB.US.md)
- [LABU.US](https://longbridge.com/zh-HK/quote/LABU.US.md)
- [IBBQ.US](https://longbridge.com/zh-HK/quote/IBBQ.US.md)

## 相關資訊與研究

- [ADHD 用藥「利他能」缺貨...網友疑考季因素 食藥署：藥廠早通知控貨中](https://longbridge.com/zh-HK/news/286754700.md)
- [巨生醫獲 SelectUSA 醫療科技組金牌 啟動美國 A 輪募資目標 1000 萬美元](https://longbridge.com/zh-HK/news/286905054.md)
- [再生元製藥因第三階段黑色素瘤試驗失敗股價下跌 10%。那麼，接下來 REGN 股票會如何表現呢？](https://longbridge.com/zh-HK/news/286811938.md)
- [鉅亨速報 - Factset 最新調查：碩騰 ZTS-US 的目標價調降至 117 元，幅度約 10%](https://longbridge.com/zh-HK/news/286769910.md)
- [市場聚焦：再生元製藥黑色素瘤試驗受挫引發更廣泛的質疑](https://longbridge.com/zh-HK/news/286769076.md)